Evidence map›Paper›PMID 42204384›Full record

ArticleEuropean journal of haematology2026

Junctional Adhesion Molecule-A (JAM-A) Associates With High-Risk Disease in Multiple Myeloma Patients and a Structure-Based Rationally-Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo.

Niamh McAuley, Roisin McAvera, Dimitri Bong, Lara Donnelly, Izabela Cymer, Marian Brennan, Joanna Fay, Lance Hudson, John Quinn, Siobhan V Glavey and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Niamh McAuleyDepartment of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Roisin McAveraMyeloma Research Group, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Dimitri BongDepartment of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Lara DonnellyDepartment of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Izabela CymerDepartment of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Marian BrennanSchool of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Joanna FayDepartment of Pathology, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Lance HudsonDepartment of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
John QuinnDepartment of Haematology, Beaumont Hospital, Dublin, Ireland.
Siobhan V GlaveyMyeloma Research Group, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Ann M HopkinsDepartment of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland.ORCID https://orcid.org/0000-0003-2836-6584

Funding

Breakthrough Cancer ResearchHealth Research BoardHealth Research Charities Ireland (to A.M.H. and S.V.G.) HRCI-HRB-2022-020
6 · The paper itself

Abstract

Multiple myeloma (MM) is an incurable malignancy of terminally-differentiated plasma cells that represents a major clinical challenge despite unprecedented therapeutic advances, particularly for patients with cytogenetically-defined high-risk MM (HR-MM). Updated in 2025, the evolving cytogenetic classification of HR-MM includes gains or amplifications in chromosome 1q. One gene of emerging interest on chromosome 1q is F11R, which codes for a protein called Junctional Adhesion Molecule-A (JAM-A). Upregulation of JAM-A has been linked with the development of several aggressive malignancies, most recently MM. In the current study, F11R gene expression was found to be significantly higher in gain/amp(1q) MM patients from the CoMMpass database, and to correlate with poorer overall survival in MM patients. Furthermore, elevated F11R expression was accompanied by an increased burden of circulating CD138

Indexed as

Antineoplastic AgentsCell Adhesion MoleculesJunctional Adhesion Molecule AMultiple MyelomaPeptidesReceptors, Cell SurfaceAnimalsCell Line, TumorChick EmbryoDisease Models, AnimalGene Expression Regulation, NeoplasticHumansMiceXenograft Model Antitumor AssaysAntineoplastic AgentsCell Adhesion MoleculesF11R protein, humanJunctional Adhesion Molecule APeptidesReceptors, Cell Surfacechorioallantoic membranechromosome 1qhigh‐risk myelomain ovoin vivojunctional adhesion molecule‐amultiple myelomanovel therapiesprecision medicine

Identifiers

PMID42204384
PMCPMC13542863

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.